These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365 [TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243 [TBL] [Abstract][Full Text] [Related]
6. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC). Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580 [TBL] [Abstract][Full Text] [Related]
7. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma. Zheng B; Mao JH; Qian L; Zhu H; Gu DH; Pan XD; Yi F; Ji DM Cancer Lett; 2015 Feb; 357(2):468-75. PubMed ID: 25444920 [TBL] [Abstract][Full Text] [Related]
8. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition. Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559 [TBL] [Abstract][Full Text] [Related]
9. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis. Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809 [TBL] [Abstract][Full Text] [Related]
10. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer. Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224 [TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2. Harada K; Miyake H; Kumano M; Fujisawa M Br J Cancer; 2013 Oct; 109(9):2389-95. PubMed ID: 24091619 [TBL] [Abstract][Full Text] [Related]
12. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. Cirstea D; Santo L; Hideshima T; Eda H; Mishima Y; Nemani N; Mahindra A; Yee A; Gorgun G; Hu Y; Ohguchi H; Suzuki R; Cottini F; Guichard SM; Anderson KC; Raje N Mol Cancer Ther; 2014 Nov; 13(11):2489-500. PubMed ID: 25172964 [TBL] [Abstract][Full Text] [Related]
13. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989 [TBL] [Abstract][Full Text] [Related]
14. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer. Korets SB; Musa F; Curtin J; Blank SV; Schneider RJ Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308 [TBL] [Abstract][Full Text] [Related]
15. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. English DP; Roque DM; Carrara L; Lopez S; Bellone S; Cocco E; Bortolomai I; Schwartz PE; Rutherford T; Santin AD Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800 [TBL] [Abstract][Full Text] [Related]
16. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Flannery PC; DeSisto JA; Amani V; Venkataraman S; Lemma RT; Prince EW; Donson A; Moroze EE; Hoffman L; Levy JMM; Foreman N; Vibhakar R; Green AL Oncol Rep; 2018 Feb; 39(2):455-464. PubMed ID: 29207163 [TBL] [Abstract][Full Text] [Related]
17. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. Li Q; Song XM; Ji YY; Jiang H; Xu LG Biochem Biophys Res Commun; 2013 Nov; 440(4):701-6. PubMed ID: 24103749 [TBL] [Abstract][Full Text] [Related]
18. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells. Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608 [TBL] [Abstract][Full Text] [Related]